BELITE BIO, INC (ticker: BLTE) is an NASDAQ-listed pharma company. DredgeCap's structured extraction of BLTE's SEC filings surfaces 1 active risk signal, including 1 auditor-change signal. BLTE reported no tagged revenue in revenue and -$77.61M for the period ending 2025-12-31, with operating cash flow of -$36.99M. Cash and equivalents stood at $352.93M (up 1014.2% year-over-year). Total assets of $780.56M exceed total liabilities of $10.07M. Each signal on this page is sourced verbatim from the underlying SEC filing. Use the tabs above to drill into auditor history, going-concern citations, dilution mechanics, cash runway, and the full risk-flag inventory.
BLTE SEC Filings
Full cached SEC EDGAR filing history for BLTE, grouped by form type and sorted newest-first within each group. 0 filings across 0 form types.
Filings sourced verbatim from SEC EDGAR submissions metadata. “Structured” links route to DredgeCap's per-filing renderer (XBRL-backed financials + cited highlights) when available; the EDGAR link always points to the canonical accession index on sec.gov.